Blocking SIK2 with GRN-300 to boost PARP therapy and T-cell attack in ovarian cancer
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
See if adding GRN-300, a drug that blocks SIK2, can help PARP medicines work better and strengthen the immune system's T cells in people with ovarian cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11413292 on NIH RePORTER |
What this research studies
Researchers are working with GRN-300, a SIK2 blocker, to try to make PARP inhibitor drugs more effective against ovarian cancer. They will study the combination in lab models and in patient-derived tumor samples, measuring cancer cell kill and the activity of cytotoxic T cells. The project is run at MD Anderson and may include translational work that informs early clinical testing and sample collection from patients. Findings will be used to design future trials if the combination appears safe and promising.
Who could benefit from this research
Good fit: People with ovarian cancer, especially those receiving or eligible for PARP inhibitor therapy (for example patients with BRCA mutations or other DNA-repair defects), would be the most relevant candidates.
Not a fit: People without ovarian cancer or whose tumors are not candidates for PARP inhibitor therapy are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this approach could help tumors that stop responding to PARP inhibitors become sensitive again and improve immune-mediated tumor control.
How similar studies have performed: PARP inhibitors are established treatments in ovarian cancer and combination strategies to overcome resistance have shown promise in preclinical and early clinical studies, but targeting SIK2 with GRN-300 is a newer approach that is largely untested in patients.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Bast, Robert C — University of Tx Md Anderson Can Ctr
- Study coordinator: Bast, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.